Recursion Pharmaceuticals

High-Level Overview

Recursion Pharmaceuticals is a clinical-stage TechBio company that develops an AI-powered drug discovery platform called the Recursion Operating System (Recursion OS) to decode human biology and industrialize the creation of new medicines.[1][2][3] It serves patients with high-unmet-need conditions, primarily in oncology and rare diseases, by addressing the 90% failure rate of traditional drug discovery through massive data generation, machine learning, and automated labs that map cellular behaviors and identify first-in-class or best-in-class therapeutics.[1][2][5] The platform has produced a robust clinical pipeline, including REC-4881 for Familial Adenomatous Polyposis (FAP) with data expected in December 2025, and demonstrates faster hit identification (weeks vs. years) at lower costs (thousands vs. millions).[1][5][6] Growth momentum stems from 65 petabytes of proprietary biological and chemical data, partnerships with pharma giants and tech leaders like NVIDIA and Google Cloud, and BioHive-2, biopharma's most powerful supercomputer.[2][3]

Origin Story

Founded in 2013 in Salt Lake City, Utah, Recursion emerged from the insight that imaging cells and training AI on those images could unlock the unknown biological space driving diseases.[2][3] Co-founders, including CEO Chris Gibson (a trained physician-scientist), recognized the inefficiencies of traditional drug discovery and pivoted to a hybrid approach blending experimental biology, bioinformatics, and AI in a lab-to-cloud platform.[3] Early traction came from building one of the world's largest proprietary datasets through automated wet labs running millions of experiments weekly, feeding into a feedback loop that rapidly scaled discoveries and reduced development timelines by up to 10x compared to industry averages.[2][3]

Core Differentiators

• Recursion OS Platform: A full-stack, AI-driven system powered by 65 petabytes of multimodal data (phenomics, transcriptomics, proteomics, ADME, patient data) that builds "Maps of Biology and Chemistry" to explore uncharted disease areas without predefined hypotheses, enabling hundreds of programs to be evaluated in parallel.[1][2][4][5]
• Industrialized Workflows: Automated labs with robotics and computer vision generate terabytes of data weekly, integrated with machine learning and LLMs for rapid target identification, molecule design, and validation—achieving hits in weeks for thousands of dollars vs. years and millions traditionally.[2][4][5]
• Precision Chemistry and Selectivity: Designs highly optimized, selective compounds like REC-617 (CDK7 inhibitor for solid tumors) and REC-4881, with advantages in half-life and toxicity management for first/best-in-class potential.[1][6]
• Strategic Partnerships and Infrastructure: Collaborations with Big Pharma, Exscientia for chemistry, NVIDIA for BioHive-2 supercomputing, and Google Cloud accelerate scale and generative AI capabilities.[2][3][5]

Role in the Broader Tech Landscape

Recursion rides the AI-for-drug-discovery trend, merging TechBio with massive compute to "industrialize" a historically artisanal process amid exploding biological data complexity.[1][2][4] Timing aligns with advances in supercomputing, cloud AI, and multimodal datasets, countering pharma's high failure rates and $2.6B average drug cost by enabling hypothesis-free exploration across rare and common diseases.[3][5] Market forces like aging populations, rare disease incentives, and AI investments favor it, as seen in its pipeline traction and partnerships that amplify reach.[2] It influences the ecosystem by open-sourcing insights, partnering with tech titans, and proving scalable TechBio models that could shift 90% of discovery failures.[1][2]

Quick Take & Future Outlook

Recursion is poised to advance its pipeline with key readouts like TUPELO Phase 2 data for REC-4881 in December 2025, potentially validating its platform in rare diseases while expanding oncology programs like REC-617.[1][6] Trends in generative AI, larger foundation models, and next-gen data partnerships will fuel faster iterations and more first-in-class assets, with BioHive-2 enabling trillion-scale computations.[2][3] Its influence may evolve from pioneer to industry standard-setter, decoding biology at unprecedented scale to deliver better medicines faster—radically improving lives as promised.[1][2]